Table 1.
Overview of experimental groups, sample sizes, and variables
| Experiment | Total mice | Survival time | Virus treatment and titer | Imaging |
|---|---|---|---|---|
| CTB colabel (uninjured) | 13 | 3, 7, or 14 d | Retro-AAV-tdTomato (3.8 × 1012 GC/ml) | 2D |
| Retro-AAV-EGFP (3.9 × 1012 GC/ml) | ||||
| CTB colabel (injured) | 8 | 28 d | Retro-AAV-tdTomato (3.8 × 1012 GC/ml) | 2D |
| Cervical retrograde (3D) | 4 | 2 weeks | Retro-AAV-tdTomato (3.8 × 1012 GC/ml) | 3D |
| Dual label (cervical/lumbar) (3D) | 4 | 4 weeks | Retro-AAV-tdTomato (3.8 × 1012 GC/ml) | 3D |
| Retro-AAV-EGFP (3.9 × 1012 GC/ml) | ||||
| DREADD behavior, wild-type | 12 | Behavior weeks 2–4; killed at 4 weeks | Retro-AAV-CRE (8.1 × 1012 GC/ml) | 2D |
| Retro-AAV-Flex-Gi-DREADD (9.0 × 1012 GC/ml) | ||||
| DREADD behavior, CaMKIIa-Cre | 6 | Behavior weeks 2–4; killed at 4 weeks | Retro-AAV-Flex-Gi-DREADD (9.0 × 1012 GC/ml) | 2D |
Statistical comparisons of transduction efficiencies between all suprapsinal populations are provided in Table 1-2.